Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ALPN | Common Stock | Exercise of in-the-money or at-the-money derivative security | $1.85M | +145K | +9.79% | $12.74 | 1.63M | Dec 11, 2023 | By: Frazier Life Sciences VIII, L.P. | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ALPN | Warrant (Right to Buy) | Exercise of in-the-money or at-the-money derivative security | $0 | -145K | -100% | $0.00* | 0 | Dec 11, 2023 | Common Stock | 145K | $12.74 | Direct |
Id | Content |
---|---|
F1 | The shares of Common Stock are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper is one of two managing members of FHM LLC. Dr. Topper disclaims beneficial ownership of the securities held by FLS LP except for his pecuniary interest therein, if any. |